ArticleAdvanced materials interfaces2025
Antibiotic-Mediated Plasmonic-Mie Resonance for Biosensing Applications on a Novel Silicon Nanopillar Metasurface.
Article in Advanced materials interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
This study demonstrates a biosensing platform facilitated by localized surface plasmonic resonance (LSPR) on a silicon (Si) nanopillar metasurface mediated by the presence of cephalexin (Cef) antibiotics in solution. The metasurface is designed to exhibit narrow quadrupolar Mie resonances that when coupled with bovine serum albumin-coated (BSA-coated) plasmonic gold nanospheres (BSANS) will produce an appreciable redshift at the peak resonance wavelength, occurring only in the presence of the target antibiotic. To optimize the performance of the Si nanopillars, the finite element method is utilized to fine-tune their diameters, heights, and periodicity, along with improvements to the fabrication techniques, under the BSANS-antibiotic binding assay. The metasurface sensor is directly fabricated via a facile photolithographic process using silicon wafers. Through the detection assay, this device exhibited a significant 22 nm wavelength shift resulting from changes to the local refractive index in the presence of the BSANS-antibiotic coupling. This phenomenon is facilitated through the presence of cephalexin down to 0.3 μg mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.